JYLAMVO

This brand name is authorized in Austria, Estonia, Finland, Croatia, Ireland, Lithuania, Poland, Romania, United Kingdom

Active ingredients

The drug JYLAMVO contains one active pharmaceutical ingredient (API):

1 Methotrexate UNII YL5FZ2Y5U1 - METHOTREXATE

Methotrexate (4-amino-10-methylfolic acid) is a folic acid antagonist which inhibits the reduction of folic acid and increase of tissue cells. Methotrexate enters the cell through an active transport mechanism of reduced folates. As a result of polyglutamation of methotrexate caused by the folylpolyglutamylate enzyme, the duration of the cytotoxic effect of the drug substance in the cell increases. Read about Methotrexate

Medication package inserts

Below package inserts are available for further reading:

Title	Information Source	Document Type
JYLAMVO Oral solution	European Medicines Agency (EU)	MPI, EU: SmPC

Medicine classification

This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:

ATC code	Group title	Classification
L01BA01	Methotrexate	L Antineoplastic and immunomodulating agents → L01 Antineoplastic agents → L01B Antimetabolites → L01BA Folic acid analogues
Discover more medicines within L01BA01

Authorization and marketing

This drug has been assigned below unique identifiers within the countries it is being marketed:

Country	Identification scheme	Identifier(s)
Country: EE	Ravimiamet	Identifier(s): 1742587
Country: FI	Lääkealan turvallisuus- ja kehittämiskeskus	Identifier(s): 185130
Country: GB	Medicines & Healthcare Products Regulatory Agency	Identifier(s): 348711
Country: LT	Valstybinė vaistų kontrolės tarnyba	Identifier(s): 1082615
Country: PL	Rejestru Produktów Leczniczych	Identifier(s): 100386812
Country: RO	Agenția Națională a Medicamentului și a Dispozitivelor Medicale	Identifier(s): W65904001